S.L. MOROZOV^{1, 2}, V.V. DLIN¹

¹Scientific-research Clinical Institute for Pediatrics named after Acad. Yu.E. Veltishchev, Moscow

²Russian Scientific-research Medical University named after N.I. Pirogov, Moscow

 Contact:

Morozov S.L. ― PhD (medicine), Senior Researcher of the Department of Inherited and Acquired Kidney Diseases, Associate Professor of the Department of Hospital Pediatrics No. 2 of Pediatrics Faculty

Address: 2 Taldomskaya Str., 125412, Moscow, Russian Federation, tel. +7-903-138-77-32, e-mail: mser@list.ru

 The article presents data on steroid therapy of primary nephrotic syndrome in children. Unfortunately, to date, modern guidelines for the treatment of nephrotic syndrome are based on empirical recommendations, and among doctors there is great variability in the treatment of nephrotic syndrome, especially relapses and the choice of immunosuppressive therapy. The article provides data on the molecular basis of the steroids action in nephrotic syndrome and assesses the prospects for a personalized approach to therapy.

Key words: сhildren, primary nephrotic syndrome, glucocorticosteroids, polymorphisms, personalized therapy. 

REFERENCES

1. Schijvens A.M. et al. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatr. Nephrol,2019, vol. 34, no. 3, pp. 389-403.
2. El Bakkali L. et al. Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature. Pediatr. Nephrol, 2011, vol. 26, no. 8, pp. 1241-1246.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl,  no. 2, pp. 139-274.
4. Teeninga N. et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J. Am. Soc. Nephrol, 2013, vol. 24, no. 1, pp. 149-159.
5. Tarshish P. et al. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J. Am. Soc. Nephrol, 1997, vol. 8, no. 5, pp, 769-776.
6. Morozov S.L., Dlin V.V., Sukhorukov V.S., Voronkova A.S. Molecular nephropathology: new possibilities for the diagnosis of kidney diseases. Rossiyskiy vestnik perinatologii i pediatrii, 2017, vol. 62, no. 3, pp. 32-36 (in Russ.).
7. Bierzynska A. et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int, 2017, vol. 91, no. 4, pp. 937-947.
8. Prikhodina L.S., Papizh S.V., Stolyarevich E.S., Povilaytite P.E., Shatalov P.A. Infantile nephrotic syndrome: clinical and morphological characteristics, genetic heterogeneity, outcomes. the experience of one center. Nefrologiya i dializ, 2019. vol. 21, no. 4, pp. 234-242 (in Russ.).
9. Morozov S.L., Voronkova A.S., Dlin V.V., Turkina T.I., Sukhorukov V.S. Analysis of gene expression using ncounter nanostring technology in medical research: experience of use in children with nephrotic syndrome. Rossiyskiy vestnik perinatologii i pediatrii, 2019, vol. 64, no. 1, pp. 110-115 (in Russ.).
10. Morozov S.L. Features of gene expression of the immune system in steroid-resistant nephrotic syndrome. Rossiyskiy vestnik perinatologii i pediatrii, 2018, vol. 63, no. 4, pp. 221-222 (in Russ.).
11. Bierzynska A., Saleem M. Recent advances in understanding and treating nephrotic syndrome. F1000Res, 2017, vol. 6, p. 121.
12. Vivarelli M. et al. Minimal Change Disease. Clin J Am Soc Nephrol, 2017, vol. 12, no. 2, pp. 332-345.
13. Weinshilboum R., Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov, 2004, vol. 3, no. 9, pp. 739-748.
14. Evans W.E., McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med, 2003, vol. 348, no. 6, pp. 538-549.
15. Ponec M. et al. Glucocorticoids: binding affinity and lipophilicity. J Pharm Sci, 1986, vol. 75, no. 10, pp. 973-975.
16. Barnes P.J. Mechanisms and resistance in glucocorticoid control of inflammation. J. Steroid Biochem. Mol. Biol, 2010, vol. 120, no. 2-3, pp. 76-85.
17. Payne D.N., Adcock I.M. Molecular mechanisms of corticosteroid actions. Paediatr Respir Rev, 2001, vol. 2, no. 2, pp. 145-150.
18. PubMed entry.
19. Czock D. et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet, 2005, vol. 44, no. 1, pp. 61-98.
20. Teeninga N. et al. Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome. Ther Drug Monit, 2016, vol. 38, no. 4, pp. 534-545.
21. Zürcher R.M., Frey B.M., Frey F.J. Impact of ketoconazole on the metabolism of prednisolone. Clin. Pharmacol. Ther, 1989, vol. 45, no. 4, pp. 366-372.
22. Bergmann T.K. et al. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet, 2012, vol. 51, no. 11, pp. 711-741.
23. Frey F.J. et al. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation, 1987, vol. 43, no. 4, pp. 494-498.
24. Ekka B.K., Bagga A., Srivastava R.N. Single-versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr. Nephrol, 1997, vol. 11, no. 5, pp. 597-599.
25. Xing C.-Y. et al. Direct effects of dexamethasone on human podocytes. Kidney Int, 2006, vol. 70, no. 6, pp. 1038-1045.
26. Wada T. et al. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J. Am. Soc. Nephrol, 2005, vol. 16, no. 9, pp. 2615-2625.
27. Che R., Zhang A. Mechanisms of glucocorticoid resistance in idiopathic nephrotic syndrome. Kidney Blood Press. Res, 2013, vol. 37, no. 4-5. pp. 360-378.
28. Duma D., Jewell C.M., Cidlowski J.A. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol, 2006, vol. 102, no. 1-5, pp. 11-21.
29. Teeninga N. et al. Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney Int, 2014, vol. 85, no. 6, pp. 1444-1453.
30. Suvanto M. et al. Single Nucleotide Polymorphisms in Pediatric Idiopathic Nephrotic Syndrome. Int J Nephrol, 2016, vol. 2016, pp. 1417456.
31. Du N. et al. Association of single-nucleotide polymorphism in the FKBP5 gene with response to steroids in pediatric patients with primary nephrotic syndrome. Clin. Nephrol, 2017, vol. 88, no. 12, pp. 338-343.
32. Jafar T. et al. Cytokine gene polymorphism in idiopathic nephrotic syndrome children. Indian J Clin Biochem, 2011, vol. 26, no. 3, pp. 296-302.
33. Vivarelli M. et al. Association of the macrophage migration inhibitory factor ― 173*C allele with childhood nephrotic syndrome. Pediatr. Nephrol, 2008, vol. 23, no. 5, pp. 743-748.